NEW YORK, July 1-Digene said today that it has terminated its merger with Cytyc, effective June 30.
Last week, the U.S. Federal Trade Commission said it would oppose the merger as a violation of anti-trust laws.
The two companies market screening tests for cervical cancer. Cytyc has the market-leading liquid Pap smear kit, and Digene offers the only FDA approved test for human papilloma virus, which is implicated in cervical cancer.
Cytyc announced its plans to acquire Digene in February 2002.
For further information, see the Digene website. ///issues/news//120495-1.html"